Øystein Bruserud

Haukeland University Hospital — Norway

Medicine · Health Sciences

51h-index10.5kcitations407works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(168), Hematopoietic Stem Cell Transplantation(71), Histone Deacetylase Inhibitors Research(45), Immune Cell Function and Interaction(43), Retinoids in leukemia and cellular processes(32)

Publications407 total

Phenazine 5,10-dioxide analogues as potential therapeutics in AML: Efficacy on patient-derived blasts, in zebrafish larvae xenografts and synergy with venetoclax
Translational Oncology·2025Open Access
NUP214 in Acute Myeloid Leukemia
Cells·2025Open Access
Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34+ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosis
Proteomes·2025· 4 citedOpen Access
XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting
Biomolecules·2025· 1 citedOpen Access
Future biomarkers for acute graft-versus-host disease: potential roles of nucleic acids, metabolites, and immune cell markers
Expert Review of Clinical Immunology·2024· 7 cited
Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies
International Journal of Molecular Sciences·2024· 14 citedOpen Access
Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations
International Journal of Molecular Sciences·2024· 3 citedOpen Access
Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival
Cancers·2024· 2 citedOpen Access
Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification
Annals of Hematology·2024· 8 citedOpen Access
High Mitochondrial Protein Expression as a Potential Predictor of Relapse Risk in Acute Myeloid Leukemia Patients with the Monocytic FAB Subtypes M4 and M5
Cancers·2023· 8 citedOpen Access
The Disease-specific Survival From Plasma Il-1 and Il-6 Families Cytokines With Associated Soluble Receptors at Diagnosis in Patients With Head and Neck Squamous Cell Carcinoma Importance of Tnm Stage and Smoking History
Research Square (Research Square)·2023Open Access
High Mitochondrial Protein Expression as a Potential Predictor of Relapse Risk in Acute Myeloid Leukemia Patients with the Monocytic FAB subtypes M4 and M5
Preprints.org·2023· 1 citedOpen Access
Adult presentation of ornithine transcarbamylase deficiency: a possible cause of hyperammonemia after high-dose chemotherapy and stem cell transplantation
Hematology·2023· 3 citedOpen Access
Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
Journal of Clinical Medicine·2023· 9 citedOpen Access
Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
Cancers·2023· 14 citedOpen Access
Supplementary Figure S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
2023Open Access
Supplementary Figure S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
2023Open Access
Data from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
2023Open Access
Supplementary Table S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
2023Open Access
Supplementary Table S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
2023Open Access
page 1 of 21Next →

Frequent Co-authors

Bjørn Tore Gjertsen(25), Håkon Reikvam(12), Kimberley Joanne Hatfield(11), Elisabeth Ersvær(8), Anita Ryningen(8), Randi Hovland(6), Anne M. Øyan(6), Astrid Olsnes Kittang(5), Camilla Stapnes(3), Kristoffer Sand(3), Karen Marie Hagen(3), Karl H. Kalland(3), Tien‐sheng Huang(3), Line Wergeland(3), Knut Liseth(3), Annette K. Brenner(3), Ina Nepstad(3), Tor Henrik Anderson Tvedt(3), Karl‐Henning Kalland(3), Jonathan M. Irish(2)